Home › Funds › Patient Square Capital LP › MIRM
Patient Square Capital LP position in MIRM
MIRUM PHARMACEUTICALS INC · Health Care
Patient Square Capital LP reported holding 234,000 shares of MIRM (MIRUM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$20.0M, representing 3.19% of its reported portfolio and ranking #8 among its reported holdings. Patient Square Capital LP has disclosed MIRM holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's MIRM position evolved
Patient Square Capital LP first disclosed a stake in MIRM in Q4 2024 at 64,900 shares (US$2.7M). The position peaked in Q2 2026 at 260,500 shares, worth US$30.5M. Across 8 filings, Patient Square Capital LP increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 234,000 shares valued at US$20.0M — a reduction of -26,500 shares quarter over quarter.. Notable position changes include a 79% increase in Q1 2025 (shares rose 13% over the following quarter), a 186% increase in Q4 2025 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 64.90K | $2.68M | New |
| Q1 2025 | 116.36K | $5.24M | Add |
| Q2 2025 | 113.46K | $5.77M | Reduce |
| Q3 2025 | 104.26K | $7.64M | Reduce |
| Q4 2025 | 298.68K | $23.59M | Add |
| Q1 2026 | 230.00K | $21.25M | Reduce |
| Q2 2026 | 260.50K | $30.50M | Add |
| Q3 2026 | 234.00K | $20.00M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MIRM and 13F data
MIRM (MIRUM PHARMACEUTICALS INC) is a Health Care company. 49 other funds we track also report a position in MIRM — the largest reported positions include Frazier Life Sciences Management, L.P. (US$899.1M), EVENTIDE ASSET MANAGEMENT, LLC (US$146.2M), TANG CAPITAL MANAGEMENT LLC (US$144.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MIRM
- Frazier Life Sciences Management, L.P. 7.68M sh · $899.06M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.25M sh · $146.20M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.24M sh · $144.70M · Q2 2026
- Novo Holdings A/S 1.12M sh · $131.70M · Q2 2026
- TCG Crossover Management, LLC 1.06M sh · $124.33M · Q2 2026
- BVF INC/IL 1.06M sh · $123.63M · Q2 2026
- Rock Springs Capital Management LP 798.14K sh · $93.44M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 24.65M sh · $91.66M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 18.45M sh · $68.30M · Q2 2026
- BAKER BROS. ADVISORS LP 445.98K sh · $52.21M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 415.64K sh · $48.66M · Q2 2026
- Palo Alto Investors LP 348.81K sh · $40.83M · Q2 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held MIRM?
Patient Square Capital LP has disclosed MIRM holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Patient Square Capital LP's current position in MIRM?
As of Q3 2026, Patient Square Capital LP holds 234.00K shares of MIRM (MIRUM PHARMACEUTICALS INC), valued at $20.00M, representing 3.19% of its reported portfolio and ranking #8.
Has Patient Square Capital LP been buying or selling MIRM?
In the latest 13F filing (Q3 2026), Patient Square Capital LP reduced its position in MIRM. The position peaked in Q2 2026 at 260.50K shares.
Which other funds hold MIRM?
Other major institutional holders of MIRM include Frazier Life Sciences Management, L.P., EVENTIDE ASSET MANAGEMENT, LLC, TANG CAPITAL MANAGEMENT LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.